The study aims to investigate the safety and efficacy of DRL-17822 in patients with type-II dyslipidemia.
In the study, three doses (50, 150 & 300mg) of DRL-17822 given once daily for 4 weeks will be investigated.
Dr Reddy’s founder chairman Anji Reddy said this class of therapy can transform the treatment of CHD and DRL-17822 is in a position to be one of the front-running products in the class.